NEW YORK — Biotechnology company OncoOne has entered into an agreement with GenScript ProBio, a contract development and manufacturing organization, to develop and manufacture therapeutic and diagnostic monoclonal antibodies targeting the oxidized macrophage migration inhibitory factor, or oxMIF, to treat cancer.
Vienna-based OncoOne has identified oxMIF as a potential immuno-oncology target, finding it to be the disease-related isoform of the macrophage migration inhibitory factor. According to the company, oxMIF is involved in immune evasion and immune tolerant phenotypes in cancer and could be harnessed to treat solid tumors, including colorectal, lung, pancreatic, and ovarian tumors.
Under this agreement, OncoOne and New Jersey-based GenScript ProBio will partner to bring candidate monoclonal antibodies against oxMIF to the clinic. Based on this partnership, OncoOne said it expects to have its first two oxMIF candidates, the therapeutic ON203 and the companion radio-labeled diagnostic ON102, enter Phase I clinical trials in 2023.
Financial terms of the agreement were not disclosed.